Experience in production of 68Ga-DOTA-NOC for clinical use under an Expanded Access IND-Reference-Cited by-同舟云学术

Experience in production of 68Ga-DOTA-NOC for clinical use under an Expanded Access IND

Published:2016-10 Issue: Volume:116 Page:63-68
ISSN:0969-8043
Container-title:Applied Radiation and Isotopes
language:en
Short-container-title:Applied Radiation and Isotopes

Author:

Green Mark A.,Mathias Carla J.,Fletcher James W.

Publisher

Elsevier BV

Subject

Radiation

Reference16 articles.

1. 21CFR312.305 Code of Federal Regulations, Title 21, Volume 5, Part 312 - Investigational New Drug Application, Subpart I - Expanded Access to Investigational Drugs for Treatment Use, Sec. 312.305 Requirements for all expanded access uses. Revised April 1, 2013.

2. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors;Ambrosini;J. Nucl. Med.,2010

3. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?;Antunes;Eur. J. Nucl. Med. Mol. Imaging,2007

4. Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue 68Ga-DOTA-NOC;Di Pierro;Appl. Radiat. Isot.,2008

5. Ethanol-based post-processing of generator-derived 68Ga toward kit-type preparation of 68Ga-Radiopharmaceuticals;Eppard;J. Nucl. Med.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Labeling with Gallium‐68;Handbook of Radiopharmaceuticals;2020-12-21

2. [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence;Molecular Imaging and Biology;2019-08-19

3. Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer;Nuclear Medicine and Biology;2017-03

4. Clinical 68Ga-PET: Is radiosynthesis module an absolute necessity?;Nuclear Medicine and Biology;2017-03